Physician profile
Paul M Mchugh
NPI 1558327692
$7,136.06
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,946 · 2020: $1,067 · 2021: $64.65 · 2022: $58.98.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,653.54 | 2019-2020 | |
| Viiv Healthcare Company | $1,170.28 | 2019-2020 | |
| Janssen Products, Lp | $871.72 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $808.45 | 2019 | |
| Amarin Pharma, INC. | $389.88 | 2019-2020 | |
| Abbvie INC. | $269.98 | 2019-2021 | |
| Janssen Biotech, INC. | $197.85 | 2019-2020 | |
| Astellas Pharma US INC | $195.38 | 2019-2020 | |
| Horizon Therapeutics Plc | $173.67 | 2019-2020 | |
| Allergan, INC. | $123.36 | 2019 | |
| Napo Pharmaceuticals INC | $110.91 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.98 | 2022 | |
| Janssen Scientific Affairs, LLC | $54.15 | 2019 | |
| Emd Serono, INC. | $31.37 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.54 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Mchugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.